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ABSTRACT  
 
INTRODUCTION: Opioid use disorder (OUD) is a debilitating and relapsing psychiatric disorder; 
opioid agonist therapy (OAT) is the front-line, evidence-supported treatment. A substantial 
number of patients relapse or continue to use heroin or other illicit drugs during OAT. There is 
considerable heterogeneity in the OAT-resistant sub-population, with many behavioural 
moderators of treatment response. We have developed a personalised psychosocial 
intervention (PSI) targeting these individuals. A formulation-guided assessment is linked to a 
toolkit of motivational, cognitive/behavioural and social support techniques. Change methods 
have been adapted from evidence-supported psychological therapies and are idiosyncratically 
tailored to the need and response.  
METHODS: In this single-centre, 18-week, parallel group, pragmatic randomised clinical trial, 
we will determine the clinical and cost-effectiveness of the PSI as an adjunctive intervention 
during OAT, in comparison to opioid agonist treatment-as-usual. We plan to recruit 368 adults. 
The primary outcome measure is the proportion of participants categorised as ‘responders’ at 
the end of the intervention (defined as self-reported abstinence from heroin and cocaine with no 
positive biological drug tests during the 28 days prior to the endpoint). Secondary outcomes 
include: percentage of days abstinent from heroin and cocaine in the 28 days before follow-up; 
treatment retention; therapy compliance; health and social functioning; exploratory genetic 
biomarkers; and analyses of treatment moderation and mediation.  
 
CONCLUSIONS: This pragmatic controlled trial determines the effectiveness and cost-
effectiveness of a personalised PSI for non-responding patients during OAT. Our intervention 
applies motivational, cognitive/behavioural and social support techniques adapted from 
evidence-based therapies. Findings will inform stratified delivery of OAT. 
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1. INTRODUCTION 
 
Non-medical opioid use is an important contributor to the global burden of disease [1]. Opioid 
use disorder (OUD) is a debilitating and relapsing psychiatric condition characterised by 
compulsive drug taking, despite significant adverse physical and psychosocial consequences 
[2]. Oral opioid agonist therapy (OAT) is the front-line medication assisted treatment, offering 
medical management of physiological dependence and access to medical and social care.  
Systematic reviews of randomised controlled trials show that OAT is effective - with marked 
reductions in illicit drug use and drug injecting, and a high level of retention in treatment [3,4,5]. 
However, a significant minority of individuals do not stop using illicit drugs during OAT [6,7]. For 
example, using national data in England, we observed that between 26-33% of patients did not 
reduce heroin use after 6 months of treatment, and 3% deteriorated to more frequent levels 
than at admission [8].  
 
Our work in community addiction clinics points to three OAT-resistant groups: intermittent 
responders - patients who stop or substantially reduce drug use in the first few weeks, but then 
relapse and cycle through periods of unsanctioned exit and re-admission; brief responders - 
patients who achieve only short periods of reduced drug use; and poor responders - patients 
who do not achieve any significant reductions in their illicit drug use, although they may stay in 
treatment for longer than average. Patients from these sub-populations might benefit from 
psychosocial interventions. However, systematic review evidence shows that specific adjunctive 
psychosocial interventions to date have not been able to increase treatment retention or help 
patients reduce drug use [9].  
 
Against this background, we contend that an idiosyncratic approach has the best chance of 
success. Our conceptualisation of addiction treatment unites three constructs: the severity of 
addiction symptoms, health and social problem complexity, and the patient’s personal recovery 
strengths. We have shown than in the day-to-day operation of addition clinics these constructs 
predict treatment response: patients with higher ratings of addiction and concurrent problem 
complexity are more likely to be using heroin or cocaine at follow-up, and those with more 
personal strengths are more likely to have achieved stable abstinence [10]. We have designed 
the current study to produce results that can be generalised and applied to routine practice 
settings. In this protocol paper, we describe the rationale, methods, analyses, strengths and 
limitations for a pragmatic randomised controlled trial (RCT) of personalised psychosocial 
intervention (PSI) during OAT to help patients abstain from heroin and cocaine (Addiction 
Recovery Clinic Trial [the ARC Trial]).  
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2.  METHODS 
 
2.1 Study design  
The ARC Trial is a single-centre, 18-week, parallel-group, pragmatic RCT of standard care OAT 
plus PSI, compared to standard care OAT. It has been designed to conform to the CONSORT 
guideline extension for such trials [11], and the Template for Intervention Description and 
Replication (TIDierR) checklist for reporting interventions [12].  
 
The study is registered (ISRCTN number: 69313751) and will be conducted according to the 
ethical principles of the Declaration of Helsinki (1996), with all members of the study team 
trained in accordance with Good Clinical Practice. Participant materials, study protocol and 
clinical research forms have been reviewed and approved by the London-Bromley Research 
Ethics Committee (reference: REC 13/LO/0640; granted 05.06.2013; first participant enrolled on 
07.06.2013).  
 
2.2 Study aims 
Among patients who have received six or more weeks of OAT and are currently using illicit 
heroin or cocaine1, the primary aim of the study is to determine the effectiveness and cost- 
effectiveness (see section 2.13.5) of OAT with a 12-week, adjunctive PSI to help patients 
abstain from heroin and cocaine. The comparison condition is OAT with standard case 
management (the treatment-as-usual condition; TAU).  
 
The secondary aims of the trial are to estimate the effectiveness of the PSI as evidenced by 
self-reported heroin and cocaine use, treatment retention, intervention adherence, craving 
response for heroin and cocaine, quality adjusted life years, and may include description of 
longer-term criminal offending and mortality. There will be exploratory analyses of treatment 
moderation and mediation using clinical measures, and targeted analyses of genetic biomarkers 
of treatment response.  
 
2.3 OAT treatment, setting and study population  
Current United Kingdom (UK) clinical guidelines recommend the following front-line oral opioid 
agonist medications: methadone (mu opioid receptor (OR) agonist: 60-120mg/day during the 
post-induction maintenance phase); and buprenorphine (partial OR: 12-32mg/day during 
maintenance; also available as a 4:1 buprenorphine-naloxone formulation). 
                                                          
1 In the UK illicit opioid using population, the smokeable base form of cocaine [colloquially known as 
crack] rather than the powder version is most commonly available. 
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The trial will be conducted at a specialist National Health Service (NHS) community addiction 
treatment centre in London operated by South London and Maudsley NHS Mental Health 
Foundation Trust. The centre admits ~15 patients per month into OAT. This is delivered by a 
multi-disciplinary team including psychiatry, psychiatric nursing, psychology and social work 
specialties. OAT patients are assigned to a member of the clinical team (known as a keyworker 
in the UK treatment system) for case co-ordination, general counselling and support. 
The study population are adults with clinically confirmed opioid use disorder (OUD; DSM-IV [2]) 
who have been enrolled in oral methadone, or oral buprenorphine, or oral buprenorphine-
naloxone OAT at the centre for at least six weeks and are classified as non-responders 
(operationally defined for the trial as continuing [or relapsing] to use heroin or cocaine use, with 
biological verification of recent drug use).  
 
We plan to recruit 368 adults. The study is estimated to take 3.5 years to complete, as follows: 
participant recruitment to month 30; clinical data collection completed by month 36; and data 
management and analysis completed by month 42.  
 
2.4 Patient eligibility and enrolment 
Participant inclusion and exclusion criteria for the study are summarised in Table 1.  
 
[Table 1, about here] 
 
Keyworkers will refer patients to the ARC Trial research team based at the centre. Electronic 
patient records will also be used to identify potential participants. At a screening visit (~30 
minutes to complete), a brief medical and social history will be recorded, including OAT 
medication check, current use of heroin and cocaine, collection of stratification factors (see 
section 2.6), and obtaining informed consent to access OAT medication, concomitant 
psychiatric medication, treatment retention and adherence information (from the electronic 
patient record)2.  
 
During screening, the visit to record baseline measures, and the outcome endpoint 
assessments (all conducted at the centre), participants will be asked to provide a urine sample. 
This will be tested for the major metabolites of heroin (morphine), cocaine (benzolyecgonine), 
and benzodiazepines (the latter for sample descriptive purposes). A tamper-proof, 48-hour 
                                                          
2 Criminal convictions and mortality data (from the police national computer and UK deaths register, 
respectively) will be collected in the longer-term and are not addressed further in this paper. 
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detection window, instant result urine drug screen (UDS) device will be used (Integrated E-Z 
Split Key Cup; www.concateno.com). For a valid test, the device’s temperature sensor will be 
required to register 92°-96°F.  
 
As part of the UDS administration process, a clinical interview will record self-reported days 
heroin, other illicit/non-medical opioids, cocaine, alcohol and non-prescribed sedative/anxiolytic 
[benzodiazepine] medication use in the previous 28 days (drug use section of the Treatment 
Outcomes Profile; [TOP; 13]). The TOP is the standard national instrument for monitoring the 
outcomes of substance use disorder treatment in England. It uses a structured, calendar-
prompt, timeline follow-back [TFLB] procedure for recall of drug consumption [14]. 
 
2.5  Assessments  
The following psychometrically robust measures will be administered prior to randomisation 
(baseline) and also during the intervention and at outcome (as shown in parentheses) and 
summarised in Table 2: 
[Table 2, about here] 
 
2.5.1  MINI international neuropsychiatric interview (DSM-IV and ICD-10 disorders; MINI; [15]; 
baseline). The MINI is a structured diagnostic assessment for diagnosis of the following current 
disorders (past year, unless otherwise stated): alcohol, opioid, cocaine use disorder; major 
depression; panic; post-traumatic stress; generalized anxiety; and anti-social personality 
(lifetime).  
 
2.5.2  Personality Disorder Screen (PDS; [16]; baseline). The PDS is a 38-item checklist 
(response: true/false) from the World Health Organization’s Composite International Diagnostic 
Interview to characterise maladaptive personality traits.  
 
2.5.3 Buss-Perry Aggression Questionnaire (BPAQ-Short-Form; [17]; baseline). The BPAQ-
SF is a 12-item scale which records expression of aggressive traits. It is the short-form of the 
29-item Aggression Questionnaire [18]. 
 
2.5.4 Barratt Impulsiveness Scale (BIS-11; [19]; baseline). The BIS-11 is a 30-item scale 
which assesses personality and behavioural aspects of impulsiveness. The BIS-11 has sub-
scales for the following latent constructs: attention, cognitive instability, motor, perseverance, 
self-control, and cognitive complexity.  
 
 7 
2.5.5 Montreal Cognitive Assessment (MoCA; [20]; baseline [version 7.1]; final follow-up 
[version 7.2]): The MoCA is a brief screening instrument for mild cognitive impairment and 
assesses attention, concentration, working memory, visuo-constructional skills, and conceptual 
thinking. A score of 26 is considered to reflect normal range functioning. An alternate version 
of the MoCA will be used at the study endpoint to decrease the risk of learning effects from 
baseline administration. 
 
2.5.6  Minnesota Craving Scale [21]; baseline, and follow-ups). The Minnesota Craving Scale 
will be adapted to assess craving response for heroin (labelled MCS-H) and cocaine (MCS-C). 
This 5-item scale records the intensity, frequency and duration of craving episodes in the past 
week. 
2.5.7 Patient Health Questionnaire (PHQ-9; [22]; baseline and final follow-up). The PHQ-9 is a 
brief scale which assesses the frequency of depressive symptoms during in past two weeks.  
 
2.5.8 Generalized Anxiety Disorder Scale (GAD-7; [23]; baseline and final follow-up). The 
GAD-7 is a brief scale which assesses the frequency of anxious thinking in the past two weeks.  
 
2.5.9 Work and Social Adjustment Scale (WSAS; [24]; baseline and final follow-up). The 
WSAS is a 5-item scale which records the extent of social functioning impairment caused by 
clinical problems in the past two weeks. 
 
2.5.10 Adult Service Use Schedule (AD-SUS; [25]; baseline and final follow-up). The AD-SUS 
is a structured interview to record patient-level health and social care resource use. It has been 
used in treatment trials with the target population. Information on services received at the centre 
and other services will also be recorded from the electronic patient record. 
 
2.5.11 EQ-5D-3L ([26]; baseline and final follow-up). The EQ-5D-3L is a brief generic scale 
which captures health-related quality of life (HRQoL) on five dimensions: mobility, self-care, 
usual activities, pain/discomfort, anxiety/depression, and with a 20cm vertical visual analogue 
scale. These responses are combined to yield a five-digit rating of HRQoL. 
 
2.5.12 Session Rating Scale (SRS; [27]; baseline and all follow-ups [PSI participants only]). The 
SRS is a 4-item visual analogue rating scale which records the participant’s rating of therapeutic 
alliance with the therapist. The SRS will be used as a measure of PSI session quality. 
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2.5.13 Outcome Rating Scale (ORS; [28]; baseline and all follow-ups [PSI participants only]). 
The ORS is a 4-item scale which records the patient’s evaluation of their intra/interpersonal and 
social functioning. The ORS will be used as an evaluation of the perceived PSI effectiveness. 
 
2.5.14 Molecular biomarker screening; baseline and final follow-up. Using a separate consent 
process, study participants in the study will be invited to provide a sample of oral fluid for 
genotyping of biomarkers of treatment response. A pre-packed set of 10 cotton 'Q-Tip' buds will 
be used for sample collection. Biological samples will be sealed in a barcoded, 15cm plastic 
collection tube containing 10ml neutral buffer solution. DNA extraction and storage will be done 
at the Social, Genetic and Developmental Psychiatric Centre at the Institute of Psychiatry, 
Psychology and Neuroscience, King’s College London.   
 
2.6 Participant randomisation 
Following completion of baseline measures, participant randomisation will be initiated. This 
procedure will be independently managed by the King’s College London Clinical Trials Unit 
(King’s CTU; www.ctu.co.uk) using a web-accessed computer programme on the King’s CTU 
server. Study participants will be randomised on a 1:1 basis to one of the two study conditions 
using block randomisation (randomly varying block sizes) with the following binary stratification 
factors (coded for the 28 days prior to baseline): cocaine use, non-medical drug injecting, and 
OAT medication (methadone or buprenorphine).  
 
The randomisation procedure will be initiated by the ARC team at the centre using a unique 
participant identification number (PIN) and password. The participant’s initials, date of birth, 
study PIN and stratification information will then be entered on the randomisation database. The 
system will then automatically allocate the participant to the PSI or TAU intervention and 
generate a confirmation email. 
 
2.7  Treatment-as-usual 
Study participants who are allocated to TAU control condition will continue to receive OAT with 
standard fortnightly case management appointments with their keyworker at the centre, for up to 
15 weeks during the study. Each of these appointments will last ~30 minutes and will include a 
medication adherence review, provision of harm reduction advice, counselling, and support to 
receive local health and social care services.  
 
For participants allocated to the TAU condition, the active period of assessment will commence 
six week’s post-randomisation to align with the timing of the PSI intervention. During TAU, there 
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may be alterations to the participant’s OAT dose or medication, which reflects routine practice. 
ARC Trial research assistants will meet with TAU participants in a clinical interview room at the 
centre to complete all outcome assessments during the intervention and at the endpoint. 
 
2.8 Theoretical framework for the experimental intervention 
Convergent lines of epidemiologic and clinical research point to several behavioural factors 
which moderate OAT effectiveness [29]. Addiction severity is moderator [30,31,32], and taking 
illicit drugs by injection correlates with higher levels of dependence and a likelihood of non-
response [33]. Concurrent cocaine use and dependence is also common among the OUD 
population in the UK, and these patients tend to have poorer engagement with the clinic and 
outcome [34,35,36]. A significant minority of patients have co-existing chronic health and social 
problems which follow, precede, or are independent of the addictive disorder, and add 
complexity to clinical management [37,38,39]. The patient’s family relationships and social 
networks may also support or hinder response [40]. We screen for these factors early in 
treatment.  
 
The PSI is founded on the evidence that there are different reasons for OAT non-response and 
that there will be no single best clinical response. Our goal is to help the patient reduce the 
symptoms of heroin and cocaine addiction, to manage or attenuate concurrent health and social 
problems, to enhance engagement with OAT, and to develop personal strengths and resources 
for recovery. 
 
2.9 Personalised psychosocial intervention  
Participants who are allocated to the PSI will continue to receive OAT and standard case 
management (fortnightly keyworker sessions ~30 minutes’ duration and regular medical 
reviews) during the study. The PSI will be delivered by the clinical psychology team at the 
centre under the supervision of the Lead Investigator (L.M) and Chief Investigator (J.M.) and 
working with the medical director (author M.K.), centre physicians, and keyworkers to optimise 
OAT medication. The evaluated PSI will be collaborative and flexible: trial psychologists will use 
a non-judgemental, collaborative counselling style (adapted from Motivational Interviewing [41]) 
and graphical representations and maps (adapted from node-link mapping to facilitate 
assessment, care planning, and progress review [42]. Our PSI represents a point of departure 
from a traditional manual-guided psychological therapy in which there may be proscription of a 
sequence of specific techniques, or multi-modal therapies which combine two or more 
therapies. We will use a ‘toolkit’ approach with specific change methods from evidence-
supported therapies are chosen collaboratively with the patient and tested for effectiveness in 
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the form of a rolling set of behavioural experiments. During development, we reviewed national 
clinical guidelines [43] and the therapist manuals for the following psychological therapies:  
 cognitive behavioural coping and skills training (CBT [44]);   
 behavioural reinforcement (‘contingency management’ using shop vouchers with clinic 
attendance and recovery activities in addition to the traditional drug abstinence operant 
reinforcer [45]; 
 behavioural psychotherapy for couples to promote relationship stability and abstinence 
reinforcement [46],  
 Social Behaviour and Network Therapy to recruit family members and others to 
accompany the patient to PSI sessions and support their recovery [47,48]; 
 12-Step Facilitation Therapy for self-help group attendance [49,50]; and  
 CBT methods for depression to help raise awareness of automatic thoughts, depressive 
evaluations and increase activity [51]. 
We selected a set of cognitive and behavioural change techniques described in these manuals 
and adapted them to our target population. Each PSI intervention will include two or more of 
these specific change techniques, with supporting participant informational and self-monitoring 
materials.  
 
Participants will be invited to attend an initial formulation session (~60 minutes) with a graduate 
or masters trained Assistant Psychologist (AP) or Senior Psychologist (SP). This session will be 
completed no later than six weeks after the participant has been randomised. The aim will be to 
developed an idiosyncratic conceptualisation of how heroin and/or cocaine use is being 
maintained during OAT, with review of the participant’s drug-related cognitions, motivations, 
drug use behaviours, and evaluations. This conceptualisation will be informed by the study 
baseline assessment battery, and the care plan will be adjusted according to response (i.e. to 
build on improvements in drug use behaviours, prevent relapse, or select different methods in 
the event of continued illicit drug use). 
 
A care plan for each participant will be brought to a weekly clinical case conference attended by 
all trial therapists with trial leads L.M. and J.M. in attendance. The participant will be invited to 
attend a programme of weekly, 60-minute, face-to-face sessions over the following 12 weeks at 
the centre with the AP. We will use brief telephone support and phone text messages to confirm 
appointments. Two additional weeks may be added to the PSI to replace missed sessions with 
advance notification (e.g. due to illness, outpatient appointments, inpatient stays, therapist 
absence and so on).  
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For those with no clinically significant cognitive impairment, the PSI typically starts with a focus 
on links between drug-related cognitions, behaviours and consequences [52,53]. For those 
patients with significant cognitive difficulties, contingency management may precede work on 
these addiction sequelae. If the participant is depressed, the PSI may be implemented as twice-
weekly sessions with a shorter duration (~30 minutes) to facilitate attention, engagement and 
clinical effectiveness.  ARC Trial research assistants will meet with PSI participants in a clinical 
interview room at the centre to complete outcome assessments during the intervention and at 
the endpoint. 
 
2.10 Treatment monitoring and fidelity 
As part of our efforts to ensure that the PSI is delivered with integrity, each session will be audio 
recorded (subject to permission) and the therapist will complete a content checklist of the 
specific techniques used in the session from the toolkit. In addition to personal supervision, 
study therapists will attend a weekly case conference with trial leads L.M. and J.M. and other 
SPs. ARC therapists will discuss practice questions using selected audio excerpts from PSI 
sessions. A random 5% sample of session recordings will be independently rated using the 
Cognitive Therapy Scale-Revised [54].  
 
2.11 Outcome measures 
2.11.1 Primary outcome 
The primary outcome measure will be recorded during a structured follow-up interview by a 
research assistant working independently from the clinical team as the proportion of participants 
who: (a) report no use of heroin or cocaine during the 28 days prior to the final follow-up 
interview after the 12-week intervention period and: (b) provide one or more negative UDS tests 
for heroin and cocaine in the 28 days prior to final follow-up and no positive tests. Patients who 
meet these criteria will be categorised as ‘responders’ on the primary outcome measure.  
 
2.11.2 Secondary outcomes 
The secondary outcomes are: (1) percentage of self-reported heroin and cocaine abstinent days 
during the 28 days prior to final follow-up interview; (2) treatment retention (defined as the 
number of days from randomisation to treatment exit); (3) treatment compliance 
(operationalised as attendance at one-third or more scheduled sessions); (4) follow-up score on 
MoCA3, PHQ-9, GAD-7, WSAS, AD-SUS and EQ-5D-3L (see section: 2.13.5 for economic 
analysis). 
 
                                                          
3 Proportion of participants falling within the normal range on the MoCA. 
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2.12 Sample size calculation 
From a meta-analysis of psychological interventions for substance use disorders, we estimate 
that the proportion of participants classified as ‘responders’ after the intervention period will be 
approximately 0.24 in the TAU and 0.42 in the PSI treatment arm [42]. We judge this to be a 
clinically significant difference.  
 
Allowing for 16% attrition (the typical rate from OAT reported by the English National Drug 
Treatment Monitoring System), an overall sample size of 368 participants will be sought. We 
estimate that a sample of 184 participants allocated to the PSI and 184 allocated to TAU will 
give 90% power to detect the anticipated 18% difference in responder status using a two-sided 
5% significance test.  
[Table 2 about here] 
 
2.13  Statistical analyses  
All analyses will be pragmatic and follow the intention to treat principle, with participants 
analysed in the group they were randomised irrespective of the duration, intensity, or quality of 
treatment received, utilising all available post-randomisation follow-up data.  
 
There are no planned interim analyses. All analyses will be completed in Stata 14 using two-
sided 5% significance tests. Main intervention effects will be summarised by study arm and 
assessment time point, with associated 95% confidence intervals.  
 
Reflecting the pragmatic nature of the study, we expect some participants to drop out of 
treatment and then be readmitted. If a participant decides to withdraw from the study, we will 
use the data collected to that point unless otherwise requested by the participant.   
 
2.13.1 Primary analysis  
The main objective of the analysis is to assess the effect of the personalised PSI on the primary 
outcome measure. Using TOP and UDS data collected at the 4, 8 and 12-week post-
randomisation follow-up, we will create a binary response outcome for each participant: self-
reported abstinence from heroin, illicit/non-medical opioids and cocaine for the preceding 28 
days, with no positive UDS tests, assessed up to 18-weeks post-randomisation (i.e. 6 weeks for 
pre-intervention case conceptualisation and treatment formulation and 12 weeks of treatment).  
 
A mixed-effects logistic regression model (Stata command meqrlogit) will be fitted for the 
primary analysis, with the following covariates: stratification factors (baseline cocaine use, non-
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medical injecting, OAT medication), treatment arm (PSI or TAU). We will fit a treatment x time 
interaction term, the time of outcome assessment (days post-randomisation and using a 
quadratic function if statistically significant), and a participant-varying random intercept and 
slope (if this significantly improves model fit). A linear combination of model coefficients will be 
used to estimate PSI effectiveness (Stata command lincom).  
 
2.13.2 Secondary analyses  
The secondary analyses (percentage of self-reported days abstinent from heroin and cocaine in 
the 28 days before final endpoint; treatment retention [days enrolled in treatment], drug use 
craving response [monthly], and the SRS and ORS session ratings) will be undertaken within a 
generalised linear model framework. These models will include the baseline measure (if 
applicable), the stratification factors and treatment arm as covariates. 
 
Where assumptions of normality do not prove to be applicable for the outcome measure, we will 
use Poisson and other extensions to ordinary linear regression models. Between treatment 
retention and adherence will be evaluated with Kaplan-Meier curves and log-rank analyses. A 
chi-squared (Fisher’s exact) test will be used to assess adverse events (see section 2.14). 
 
2.13.3 Exploratory moderation and mediation analyses  
We will estimate the moderating (interaction by trial arm) effect on the primary outcome 
measure and the drug use, treatment retention and treatment adherence secondary outcomes 
for sub-populations identified using the following baseline measures: MINI psychological and 
substance use disorders (major depressive; suicidality; panic; post-traumatic stress; anti-social 
personality; opioid; cocaine; alcohol); PBS, BPAQ-SF and the BIS-11 [55]. Following 
established methods, interaction terms will be centred and orthogonalised [56].  
 
Change in monthly scores on the MCS-H and MCS-C and alterations in OAT medication will be 
investigated as mediators of treatment effect.  
 
2.13.4 Sensitivity analysis and management of missing data 
Missing observations are expected in the dataset. The analyses will be based on maximum 
likelihood and provide valid inferences under a missing at random (MAR) assumption. In this 
context, we will empirically assess whether baseline assessments predict missingness and 
include predictors as covariates in the analysis models. A commonly used strategy in the field is 
to record missing UDS information as positive (penalized imputation). Sensitivity analyses will 
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use this approach and also assess the robustness of conclusions to missing outcome data and 
to departures from randomised treatment. 
2.13.5 Cost-effectiveness analysis  
The cost-effectiveness evaluation will take a broad, societal perspective including the impact of 
treatment on the use of all health and social services, criminal justice sector resources and 
productivity losses (time off work due to illness). The cost of the PSI therapy will be directly 
calculated taking a micro-costing approach. A cost per-hour of each therapist, including 
employer costs (National Insurance and superannuation contributions), overhead costs (capital, 
administrative and managerial etc.) and supervisor costs, will be applied to data on direct face-
to-face contact and indirect time (supervision, training, preparation). Indirect time will be 
estimated using information provided by trial therapists on the ratio of time spent in face-to-face 
contact to time spent on other activities. Resource use will be valued using national tariffs/units 
and National Health Service reference costs and applied to all services external to the centre. 
The cost of OAT and concomitant medication will be taken from the British National Formulary.  
 
The human capital approach will be applied to value productivity losses [57]. The cost of 
criminal activity will be obtained from Home Office estimates [58]. Unit costs will be multiplied by 
the corresponding service use data to generate total costs per participant. Cost differences will 
be analysed using t-tests with the validity confirmed by bias-corrected, non-parametric 
bootstrapping (i.e. repeat re-sampling [59]). All economic analyses will be adjusted for the study 
stratification factors plus baseline values of the variable of interest. Cost-effectiveness will be 
estimated using the primary outcome measure.  
 
Secondary analysis will use quality adjusted life years calculated using the EQ-5D-3L [60]. 
Cost-effectiveness will also be assessed by estimating incremental cost-effectiveness ratios. A 
joint distribution of incremental mean costs and effects for the two groups will be generated 
using non-parametric bootstrapping to explore the probability that the PSI or TAU is the better 
choice. Uncertainty around the cost and effectiveness estimates will be represented by cost-
effectiveness acceptability curves [61]. 
 
2.13.6 Exploratory genetic association analysis 
In this study of OAT treatment response, we will use a stress-response and relapse risk 
approach within an epigenetic framework to guide targeted, exploratory SNP association 
analyses from biological samples collected at baseline and at final follow-up. Reflecting the 
relatively small-scale nature of the trial, hypothesis testing will be targeted and the analysis 
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limited to dopaminergic, serotonergic, adrenergic and GABAergic biomarkers of outcome 
response. For example, we will assess for SNP variants of the FKBP5-binding protein 51 (a 
modulator of glucocorticoid receptor activity [62]) and the alpha-1 adrenoreceptor (ADRA1A; 
[63]). We will include these biomarkers in exploratory analyses of treatment moderation and 
mediation alongside targeted clinical measures and the classification of treatment response.  
 
All genetic association analysis will be conducted by laboratory collaborators who will be blind to 
trial arm. Our analysis plan may be updated for ancillary studies within this general framework in 
accordance with emergent genetic and epigenetic biological evidence.  
2.14  Data management, monitoring and study governance 
Participants’ personal data will be stored securely within the centre in individualised source data 
worksheets. Electronic case reports will be created in which participants will be identified by a 
unique code and initials (using the commercial data entry system: InferMed MACRO; 
https://www.elsevier.com/solutions/infermed). After completion of all follow-ups and prompt 
entry of data, the dataset will be reviewed for accuracy and then locked for analysis. The 
statistical analysis plan will be finalised and approved prior to treatment arm allocation 
unmasking. In addition to recording adverse events, each participant will be asked during the 
final follow-up research interview whether they have experienced anything particularly harmful 
or distressing during the study and if so, whether they believe it was related or caused by the 
interventions and procedures. This assessment will be supplemented by a review of the clinical 
record. All adverse events, adverse reactions, and serious and unexpected adverse events and 
reactions, will be recorded and reported immediately.  
 
A Data Monitoring Committee will review recruitment and safety data during the trial and report 
to a Trial Steering Committee (TSC). The TSC and DMEC will be independent from the sponsor 
and funders, and will include a statistician, clinician and clinician scientist. These committees 
will convene every 6-12 months.  
 
3.  DISCUSSION  
 
As we progress into a fifth decade since buprenorphine was discovered and methadone 
introduced, we judge that there is a strong imperative to develop and evaluate adjunctive, 
personalised psychosocial interventions for people who do not respond to OAT. The ARC Trial 
is a pragmatic study of OAT in a routine clinic setting which targets patients who continue to use 
heroin or cocaine after a minimum of 6 weeks. Finding effective means of helping these hard-to-
 16 
reach patients is important. A recent study observed that non-medical opioid use during the first 
two weeks of OAT was strongly predictive of an unsuccessful outcome at 12 weeks [64].  
We think our study has several strengths. First, the ARC Trial is open to as many members of 
the target population as possible, while protecting safety and likelihood of follow-up. Secondly, 
our primary outcome is a well-defined, clinically meaningful and stringent, and all secondary 
outcomes are recorded using validated scales. The collection of outcome measures is timed to 
coincide with routine clinical follow-up as part of our efforts to minimise loss to follow-up.  
Thirdly, we will make pragmatic use of various psychological change techniques rather than a 
fixed therapeutic manual. This allows the therapist considerable flexibility, and reflects a 
problem-service matching approach which has been promoted to direct participants to specific 
medical care and psychological interventions and supports.  
We also acknowledge several limitations. First, our findings will be limited to application in 
substance use disorder treatment centres with access to appropriately trained and supported 
psychologists and psychotherapists. Secondly, the primary outcome measure was selected to 
reflect the aim of the PSI and not rely on self-report; but it may be may be too stringent. There is 
no consensus in the illicit drug treatment field for outcome measurement, although the 
percentage of abstinent days during a follow-up period is often used (and is used in this study 
as a secondary outcome measure). It is likely that some participants who are classified as non-
responders on the primary outcome will report a reduction in drug use and our secondary 
analyses will address this response gradient.  
An integrated approach to assessment, stratified treatment and continuing care is now gaining 
momentum in behavioural medicine, where tailoring variables and decision rules are improving 
outcomes [65]. We expect the ARC Trial to contribute to this applied orientation in the 
addictions.  
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Table 1    
Participant inclusion and exclusion criteria 
 
Inclusion criteria:  
In order for a participant to be enrolled into the study they must fulfil all of the following 
inclusion criteria:   
(a) Aged 18 years (no upper limit, but usually less than 60 years); 
 
(b) Current diagnosis of OUD;  
 
(c) Enrolled in oral methadone, buprenorphine or buprenorphine-naloxone treatment for 6 weeks; 
 
(d) Self-reported use of heroin and/or cocaine (verified by urine drug screen toxicology test); 
 
(e) Voluntarily seeking continued treatment and able to attend the clinic as required in the protocol; 
 
(f)  Stable accommodation;  
 
(g) Able to communicate verbal understanding of study material and protocol in English;  
 
(h) Possession of a personal phone and ability to nominate at least one locator individual to assist 
with arranging research appointments. 
_________________________________________________________________________ 
Exclusion criteria  
Otherwise eligible individuals will be excluded from the trial for any of the following:  
 
(a) Clinically significant physical health conditions that may compromise safety or study conduct; 
 
(b) Suicide planning (past 30 days) or suicide attempt (past six months); 
 
(c) Clinically significant or uncontrolled mental health problems (including but not limited to 
psychosis, bipolar disorder, schizoaffective disorder) and/or history or evidence of organic brain 
disease or dementia that may compromise safety or compliance with the study protocol; 
 
(d) Current legal proceedings which are likely to result in imprisonment or relocation outside of the 
centre’s catchment area; 
 
(e) Participation in a SUD treatment intervention study in past six months. 
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Table 2 
Study timeline and measures  
               R 
 
 
Activity/measure 
 
Baseline  
Study Week (from randomisation to follow-up assessment)  
IT             
1-6 7 8 9 10 11 12 13 14 15 16 17 18-20 
Screening for eligibility  X              
Medical/social history X              
UDS   X    X    X    X 
MINI                
 - major depressive  X              
 - suicidality X              
 - panic  X              
 - post-traumatic stress  X              
 - anti-social personality  X              
MINI                
 - opioid X              
 - cocaine X              
 - alcohol X              
PDS X              
BPAQ-SF X              
BIS-11 X              
TOP (heroin/cocaine) X X    X    X    X 
MoCA (version 7.1) X              
MoCA (version 7.2)              X 
MCS-H  X X    X    X    X 
MCS-C X X    X    X    X 
PHQ-9 X             X 
GAD-7 X             X 
WSAS               
ADSUS X             X 
EQ-5D-3L X             X 
OAT medication X              
OAT dose * X             X 
Biomarker sampling X             X 
Concomitant medications  X X X X X X X X X X X X X X 
Adverse events form   X X X X X X X X X X X X X 
PSI duration/content   X X X X X X X X X X X X X 
SRS   X X X X X X X X X X X X X 
ORS  X X X X X X X X X X X X X 
Participant payments ** £20     £5    £5    £30 
 
Note: R, randomisation; IT, initiation of treatment (weeks 1-6);  
UDS, urine drug screen; MINI, Mini International Neuropsychiatric Interview; PDS, personality 
disorders screener; BPAQ-SF, Short-form Buss-Perry Aggression Questionnaire; BIS-11, 
Barratt Impulsiveness Scale; TOP, treatment outcomes profile;; MoCA, Montreal Cognitive 
Assessment; MCCS, Minnesota Craving Scale, MCS-C [cocaine]; MCS-H [heroin]; PHQ-9, 
Patient Health Questionnaire; GAD-7, Generalized Anxiety Disorder Scale; WSAS, Work and 
Social Adjustment Scale; AD-SUS, Adult Service Use Schedule; OAT, opioid agonist treatment; 
ORS, Outcome Rating Scale (PSI only).  SRS, Session Rating Scale (PSI only); * OAT 
additionally recorded as highest/lowest dose and any medication change between baseline and 
final follow-up; ** shop-store vouchers to value shown for completion of research measures. 
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